Learn how U.S. reimbursement mechanics—coding, coverage, and payment—should shape MedTech product design, trials, and launch strategies.
Why comparing your AI MedTech solution to the status quo isn’t enough for payer approval.
FDA clearance is a milestone—not the finish line. Why reimbursement hurdles follow right after.
A breakdown of the finalized TCET rule and what it means for Breakthrough Devices.